Eczema treatment cuts risk of death from COVID-19
Story courtesy of UVA Health
A monoclonal antibody used to treat asthma and eczema can improve survival for patients with moderate to severe COVID-19, a clinical trial conducted at UVA Health suggests.
The small trial, designed and led by Jennifer Sasson, M.D., found that dupilumab improved patient survival at 60 days and reduced the number of patients who needed intensive care.
Almost 90% of patients who received dupilumab in the randomized trial were alive at 60 days, compared with 76.2% of patients who received a placebo (a harmless, inert treatment).
“Our clinical trial suggests that treatment with the anti-allergy medicine dupilumab may decrease deaths due to COVID-19. UVA is the first to test this novel and promising approach to COVID-19 treatment, which also proved safe in this small study—as we had expected, as dupilumab has proven safe and effective as an allergy medicine,” says Sasson of the University of Virginia School of Medicine’s Division of Infectious Diseases and International Health.
“A large multi-institution study to validate these preliminary results is being designed. If successful, this multi-site trial will open a new window to treatment of COVID-19 and potentially other viral pneumonias,” she says.
Sasson and her collaborators were inspired to launch the trial after discovering that patients with COVID-19 were at significantly greater risk of needing a ventilator if their blood contained high levels of interleukin-13, a driver of inflammation in the body.
Dupilumab, sold under the brand name Dupixent, works by blocking the effects of IL-13. The federal Food and Drug Administration approved dupilumab in 2017 to treat moderate to severe eczema, an itchy skin condition known as atopic dermatitis. Dupilumab is also used to treat patients with asthma and chronic sinus inflammation.
To see if dupilumab could improve the body’s immune response to COVID-19, Sasson and her collaborators enrolled 40 patients with moderate to severe cases in a clinical trial.
The trial was double-blinded, meaning neither the patients nor the doctors knew whether the patient received the antibody or a placebo. Both groups of trial participants otherwise received standard care.
After 28 days, the two groups saw no difference in ventilator-free survival or adverse events. But by 60 days, there were only two deaths among the patients receiving dupilumab and five deaths among those receiving placebo.
Among the patients who were not already in the intensive care unit when they joined the trial, three receiving dupilumab ultimately were admitted to the ICU. That’s compared with six of those receiving placebo.
While dupilumab is not a magic bullet against COVID-19, the UVA researchers note that it could be a useful treatment for appropriate patients, especially considering the limited effectiveness of existing treatments.
They are urging larger trials to improve understanding of the monoclonal antibody’s potential benefits.
“We are indebted to the patients at UVA who consented to participate in this study, without even knowing if they would receive the medicine or placebo, as they are the ones who have advanced our understanding of the pandemic,” Sasson says.